Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Exudative age-related macular degeneration (ARMD) is complicated by choroidal
neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the
gold standard treatment, recurrence is the main limitation of the treatment. The changes of
the CNV vascular structure is expected to provide information regarding recurrence. In the
eyes that the vascular structure is clearly seen in indocyanine green angiography (ICGA), the
vascular changes after ranibizumab injections will be investigated prospectively.